Neutral
Valneva’s Credibility Test: Stock Near Lows as Lyme Vaccine Data Gives Conflicting Signals
Valneva's stock is near its 52-week low, battered by conflicting data from its Lyme vaccine candidate, LB6V, developed with Pfizer, which failed its p...